GlassScriptPhysician profile
Kaye A Linke
NPI 1265430037
$360.18
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.06 · 2020: $307 · 2022: $22.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.74 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $55.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.21 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $34.23 | 2020 | |
| Eisai INC. | $32.16 | 2020 | |
| Seagen INC. | $26.88 | 2020 | |
| Pfizer INC. | $22.78 | 2020 | |
| Incyte Corporation | $19.52 | 2020 | |
| Clovis Oncology, INC. | $13.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaye Linke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.